Related Experiment Video
Updated: Jul 16, 2026
Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
Published on: June 23, 2019
Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy
Yitzhack Ramon1, Lucian Fodor, Yehuda Ullmann
1Department of Aesthetic Surgery, Elisha Hospital, Haifa, Israel.
Background:
Highly active antiretroviral therapy for HIV-infected patients causes metabolic changes known as the lipodystrophy syndrome. Autologous fat injections, dermal fat grafts, malar implants and injected fillers have been reported as treatment options.
Objective:
To evaluate the results of HIV-infected patients treated with Bio-Alcamid for facial lipoatrophy.
Methods And Materials:
Over a 3-year period, 13 HIV-infected patients with facial lipoatrophy had Bio-Alcamid injections for aesthetic purposes. The procedure was done under local anesthesia, and the amount of the injected material varied from 5 to 13 ml. Results were independently evaluated by patients and physicians.
Results:
Most of the patients felt they had good to excellent results. Touch-ups were necessary for 2 patients; the added volume was 2-3 ml for each. No major complications were recorded. A small hematoma was noted in 1 patient. Overcorrection was attained in 2 cases, and some of the filler was removed at the patient's request.
Conclusion:
One of the greatest advantages of this filler is that, although permanent, it can be removed easily. We consider Bio-Alcamid to be a safe and useful correcting tool for patients suffering from drug-induced facial lipoatrophy.
